Sign in
CompletedNo phase

Deep Brain Stimulation in Tourette Syndrome

Key facts

Who runs it
University College, London
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
18 people enrolled
Started
2 Aug 2022
Ended
30 Jun 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Deep Brain Stimulation
Record updated
8 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Adult patients aged 18 and over:
  • with chronic, severe, treatment refractory Tourette Syndrome, as defined by a Yale Global Tic Severity Scale score (YGTSS (global)) >50/100
  • with failure to respond to a minimum of two antipsychotic drugs prescribed separately at maximally tolerated doses for a minimum of 6 weeks OR, intolerance of these medications causing early cessation due to adverse events
  • who have provided agreement to participate and written informed consent

Who cannot take part

  • Any other implanted electronic devices such as implantable cardioverter defibrillators (ICD), permanent pacemakers (PPM) and drug pumps
  • Schizophrenia or other primary psychotic disorder (schizophrenia (ICD11 6A20); delusional disorders (ICD11 6A24); schizoaffective disorder (ICD11 6A21)
  • History of substance-induced psychotic disorder (ICD11 6C40.6 Alcohol-induced psychotic disorder; ICD11 6C43.6 Opioid-induced psychotic disorder; ICD11 6C41.6 Cannabis-induced psychotic disorder; ICD11 6C42.6 Synthetic cannabinoid-induced psychotic disorder; ICD11 6C44.6 Sedative, hypnotic or anxiolytic-induced psychotic disorder; ICD11 6C45.6 Cocaine-induced psychotic disorder; ICD11 6C46.6 Stimulant-induced psychotic disorder including amphetamines, methamphetamine or methcathinone; ICD11 6C47.6 Synthetic cathinone-induced psychotic disorder; 6C49.5 Hallucinogen-induced psychotic disorder; ICD11 6C4B.6 Volatile inhalant-induced psychotic disorder; ICD11 6C4C.6 MDMA or related drug-induced psychotic disorder, including MDA; ICD11 6C4D.5 Dissociative drug-induced psychotic disorder including Ketamine or PCP; ICD11 6C4E.6 Psychotic disorder induced by other specified psychoactive substance)
  • Recurrent depressive disorder with a history of attempted suicide (ICD11 6A71)
  • Bipolar disorder (ICD11 6A60)
  • Severe personality disorder judged to be contributing to impaired social function by the physician reviewing eligibility (ICD11 6D10.2)
  • Disorders of Intellectual Development (defined as moderate intellectual disabilities (ICD11 6A00.1); severe intellectual disabilities (ICD11 6A00.2); profound intellectual disabilities (ICD11 6A00.3))
  • Autism Spectrum Disorders with exception of ICD11 6A02.0 Autism spectrum disorder without disorder of intellectual development and with mild or no impairment of functional language
  • Significant cognitive impairment as judged at the discretion of the physician reviewing eligibility
  • Contraindications to neurosurgery (such as brain abnormalities, haemostasis disorder or contraindication to MRI) or anaesthesia
  • Severe intercurrent pathology and any other disease that could interfere with the protocol or compromise life expectancy, in the Investigator's judgement
  • Pregnancy or absence of an acceptable method of contraception
  • Continued participation in any other interventional clinical trials

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Op-TICS is a clinical investigation of the use of Deep Brain Stimulation (DBS), with a CE marked implantable device, to reduce severe motor and vocal tics in patients who suffer from Tourette Syndrome (TS).

Read full original descriptionShow less

It is a randomised, double-blind, crossover clinical investigation for 20 patients. Op-TICS will be performed at the National Hospital for Neurology \& Neurosurgery.

Following DBS surgery, participants will first enter an open adjustment phase, of 6 months, where the electrical stimulation settings of the device are optimised. Participants will then enter the double-blind phase that will include successively up to 2 weeks with stimulation on and up to 2 weeks with the stimulation off in a randomised order.

The primary outcome measure is the tic severity score measured by the Yale Global Tic Severity Scale -Total Tic Score after two weeks OFF-stimulation versus two weeks ON-stimulation in the double-blind randomised crossover phase

The 2 groups in the trial

  • ON/OFF-stimulationTreatment being tested

    This group will have the stimulator switched on for two weeks followed by off for two weeks

    Treatment: Deep Brain Stimulation

  • OFF/ ON -stimulationTreatment being tested

    This group will have the stimulator switched off for two weeks followed by on for two weeks

    Treatment: Deep Brain Stimulation

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Double Blind Comparison of Optimised Deep Brain Stimulation for Severe Tourette Syndrome
Record updated
8 July 2025